Boston Scientific (BSX)
(Delayed Data from NYSE)
$73.17 USD
-0.09 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
BSX 73.17 -0.09(-0.12%)
Will BSX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
3 Medical Products Stocks Set to Beat This Earnings Season
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Other News for BSX
Top 4 Health Care Stocks That May Plunge This Month
Boston Scientific price target raised by $8 at Barclays, here's why
Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)
Upcoming Deadline to Share in Boston Scientific Corporation (BSX) Class Action Settlement
Boston Scientific price target raised by $4 at RBC Capital, here's why